GlassScriptPhysician profile
James Calvin Sutherland
NPI 1467458232
$4,593.85
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $562 · 2021: $625 · 2022: $879 · 2023: $1,320 · 2024: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.80 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $604.61 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $468.62 | 2019-2024 | Cimzia |
| Pfizer INC. | $437.38 | 2019-2024 | |
| Lilly USA, LLC | $369.00 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $314.45 | 2019-2023 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $258.96 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $242.75 | 2019-2023 | Orencia |
| Mallinckrodt Hospital Products INC. | $195.75 | 2021-2023 | Acthar |
| Glaxosmithkline, LLC. | $123.19 | 2019-2021 | |
| Genentech USA, INC. | $98.45 | 2019-2023 | Actemra |
| Celgene Corporation | $83.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.26 | 2019-2022 | |
| Sandoz INC. | $43.15 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $42.60 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $36.01 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $33.47 | 2023-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.80 | 2019 | |
| Genzyme Corporation | $25.08 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $22.59 | 2022 | |
| Ani Pharmaceuticals, INC. | $22.15 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $21.95 | 2020 | |
| Biodelivery Sciences International, INC. | $19.13 | 2020 | |
| Horizon Therapeutics Plc | $17.52 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.64 | 2023 | Zilretta |
| Octapharma USA, INC. | $15.31 | 2023 | Octagam Immune Globulin (Human) |
| Organon LLC | $8.15 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.